三博脑科（301293）(301293.SZ)公告称，公司股票于2026年1月5日、1月6日，连续2个交易日内日收盘 价格涨幅偏离值累计超过30%，属于股票交易异常波动的情形。公司是以神经专科为特色的医疗服务集 团，下属院区主要为患者提供以高精尖神经外科为主的综合医疗服务。公司目前不涉及脑机接口产品的 研发、生产及销售，神经调控技术带来的收入占公司营业收入比重很小，对公司业绩基本没有影响。 ...

格隆汇1月6日丨三博脑科(301293.SZ)公布股票交易异常波动公告，公司是以神经专科为特色的医疗服 务集团，下属院区主要为患者提供以高精尖神经外科为主的综合医疗服务。公司目前不涉及脑机接口产 品的研发、生产及销售，神经调控技术带来的收入占公司营业收入比重很小，对公司业绩基本没有影 响，敬请注意投资风险。 ...

交易行情显示，三博脑科于1月5日—6日连续两个交易日涨停，截至1月6日收盘，三博脑科报84.94元/ 股，涨幅为20.01%。 三博脑科表示，公司是以神经专科为特色的医疗服务集团，下属院区主要为患者提供以高精尖神经外科 为主的综合医疗服务。公司目前不涉及脑机接口产品的研发、生产及销售，神经调控技术带来的收入占 公司营业收入比重很小，对公司业绩基本没有影响。 北京商报讯（记者 丁宁）1月6日晚间，连续两个交易日涨停的三博脑科（301293）发布公告称，公司 股票于1月5日、1月6日，连续2个交易日内日收盘价格涨幅偏离值累计超过30%，根据《深圳证券交易 所交易规则》的规定，属于股票交易异常波动的情形。 ...

智通财经APP讯，三博脑科(301293.SZ)公告称，公司股票于2026年1月5日、1月6日，连续2个交易日内 日收盘价格涨幅偏离值累计超过30%，属于股票交易异常波动的情形。公司是以神经专科为特色的医疗 服务集团，下属院区主要为患者提供以高精尖神经外科为主的综合医疗服务。公司目前不涉及脑机接口 产品的研发、生产及销售，神经调控技术带来的收入占公司营业收入比重很小，对公司业绩基本没有影 响。 ...

三博脑科股票交易异常波动公告，公司是以神经专科为特色的医疗服务集团，下属院区主要为患者提供 以高精尖神经外科为主的综合医疗服务。公司目前不涉及脑机接口产品的研发、生产及销售，神经调控 技术带来的收入占公司营业收入比重很小，对公司业绩基本没有影响，敬请注意投资风险。 ...

资料显示，明基医院是一家民营营利性综合医院集团，目前拥有和运营两家综合医院，分别为南京明基 医院和苏州明基医院，收入主要来自提供综合医疗服务，包括住院医疗服务及门诊医疗服务。 北京商报讯（记者 丁宁）12月22日，明基医院（02581.HK）登陆港交所，上市首日，明基医院股价大 跌，收跌49.46%，收盘价为4.72港元/股。 今年上半年，明基医院营收、净利双降。财务数据显示，今年上半年，公司实现的营业收入约为13.12 亿元，同比下降1.34%；归属净利润约为4870万元，同比下降23.18%。 ...

（原标题：新股首日 | 明基医院(02581)首挂上市 早盘低开30.41% 公司为华东地区最大的民营营利性综 合医院集团） 智通财经APP获悉，明基医院(02581)首挂上市，公告显示，每股定价9.34港元，共发行6700万股股份， 每手500股，所得款项净额约5.55亿港元。截至发稿，跌30.41%，报6.5港元，成交额868.46万港元。 招股书显示，明基医院是中国内地的一家民营营利性综合医院集团，目前该公司拥有和运营南京明基医 院和苏州明基医院等两家民营营利性综合医院。根据弗若斯特沙利文的数据，以2024年总收入计，公司 是华东地区最大的民营营利性综合医院集团，于华东地区的市场份额为1.0%；以相同口径计，公司在 全国民营营利性综合医院集团中排名第七，于中国的市场份额为0.4%；以2024年的床均收入计，公司 在中国内地所有民营营利性综合医院集团中排名第一。 ...

Core Viewpoint - BenQ Hospital Group has submitted its fourth IPO application to the Hong Kong Stock Exchange, with CICC and Citigroup as joint sponsors, amidst a challenging environment for private healthcare companies seeking to go public [1][6]. Group 1: Company Overview - BenQ Hospital is a private, profit-oriented comprehensive hospital group in mainland China, operating two hospitals and leveraging operational management experience from Taiwan [1][2]. - The group is the largest private profit-oriented comprehensive hospital group in East China by total revenue for 2024, holding a 1% market share in the region and ranking seventh nationally with a 0.4% market share [1]. Group 2: Operational Performance - As of June 30, 2025, the total building area of the two hospitals is approximately 400,000 square meters, with 1,850 registered beds and over 1,000 experienced doctors, including 35 experts from Taiwan and overseas [2]. - The number of inpatient visits increased from 67,100 in 2022 to 81,900 in 2023, and further to 86,200 in 2024, with 42,400 visits in the first half of 2025 [3]. - Outpatient visits rose from 1.68 million in 2022 to 2.15 million in 2024, with 1.06 million visits in the first half of 2025 [3]. Group 3: Financial Performance - The company reported revenues of CNY 2.336 billion, CNY 2.688 billion, CNY 2.659 billion, and CNY 1.312 billion for the years 2022, 2023, 2024, and the first half of 2025, respectively, showing significant fluctuations [3]. - The net profits for the same periods were CNY 89.6 million, CNY 168 million, CNY 109 million, and CNY 48.7 million, indicating volatility in profitability [3]. - The gross profit margins were 16.4%, 18.9%, 18.1%, and 15.9% for the respective years, with a decline noted in 2024 [4]. Group 4: Market Context - The IPO attempts coincide with a wave of private healthcare companies seeking to go public, referred to as the "Odyssey Year of Private Medical IPOs" in 2023, amidst various pressures affecting investment value [5][6]. - The net proceeds from the IPO are intended for hospital expansion and upgrades, potential investments and acquisitions, smart hospital upgrades, working capital, and general corporate purposes [6]. Group 5: Shareholding Structure - BenQ Hospital is primarily controlled by Qisda Corporation, which holds 95.02% of the shares, providing a strong backing from a diversified technology group [7]. - Qisda Corporation, founded in 1984 and listed on the Taiwan Stock Exchange, operates across various sectors, including healthcare, which may offer synergistic opportunities for BenQ Hospital [7].

Core Viewpoint - BenQ Hospital Group has submitted its IPO application to the Hong Kong Stock Exchange for the fourth time, with CICC and Citibank as joint sponsors, amidst a challenging environment for private healthcare companies seeking to go public [1][2][11]. Group 1: Company Overview - BenQ Hospital is a private, profit-oriented comprehensive hospital group in mainland China, operating two hospitals and leveraging operational management experience from Taiwan [6]. - As of 2024, BenQ Hospital is the largest private profit-oriented comprehensive hospital group in East China, holding a market share of 1% in the region and ranking seventh nationally with a market share of 0.4% [6]. Group 2: Operational Performance - The two hospitals operated by BenQ Hospital have a total construction area of approximately 400,000 square meters and 1,850 registered beds, supported by a team of over 1,000 experienced doctors, including 35 experts from Taiwan and overseas [6]. - The number of inpatient visits increased from 67,100 in 2022 to 81,900 in 2023, and further to 86,200 in 2024, while outpatient visits rose from 1,680,600 in 2022 to 2,146,500 in 2024 [8]. - Revenue figures for the reporting periods were CNY 2.336 billion, CNY 2.688 billion, CNY 2.659 billion, and CNY 1.312 billion, with net profits of CNY 896 million, CNY 1.68 billion, CNY 1.09 billion, and CNY 487 million, indicating significant fluctuations [8]. Group 3: Financial Metrics - The gross profit margins for BenQ Hospital during the reporting periods were 16.4%, 18.9%, 18.1%, and 15.9%, showing a decline in 2024 [9]. - Revenue from medical services accounted for approximately 98.7% to 99% of total revenue across the reporting periods, highlighting its primary income source [8]. Group 4: Market Context - The IPO attempts by BenQ Hospital are part of a broader trend of private healthcare companies seeking to go public, referred to as the "private healthcare IPO odyssey year" in 2023, with many companies facing challenges related to policy, profitability, and valuation [11]. - The net proceeds from the IPO are intended for hospital expansion and upgrades, potential investments and acquisitions, smart hospital upgrades, working capital, and general corporate purposes [12]. Group 5: Ownership Structure - BenQ Hospital is primarily owned by Qisda Corporation, which holds 95.02% of the shares, providing a strong backing from a well-established technology and healthcare group [13].

Core Viewpoint - Ming Kee Hospital is a leading private for-profit hospital group in East China, with significant market share and a focus on providing high-quality medical services through its two hospitals in Nanjing and Suzhou [2][3]. Company Overview - Ming Kee Hospital operates two private for-profit general hospitals: Nanjing Ming Kee Hospital and Suzhou Ming Kee Hospital, making it the largest private for-profit hospital group in East China by total revenue in 2024, with a market share of 1.0% in the region and 0.4% nationally [2]. - Nanjing Ming Kee Hospital, operational since 2008, was rated as a tertiary hospital in 2022, becoming the first private hospital in Nanjing to achieve this status. It ranks as the third largest private for-profit hospital in China with a market share of 0.3% [2]. - Suzhou Ming Kee Hospital, operational since 2013, is also a tertiary hospital and has received various certifications, including from the Joint Commission International (JCI) [2]. Financial Performance - Revenue for Ming Kee Hospital was approximately RMB 2.336 billion in 2022, RMB 2.688 billion in 2023, and RMB 2.659 billion in 2024, with RMB 1.330 billion and RMB 1.312 billion for the six months ending June 30 in 2024 and 2025, respectively [5]. - Profit figures were RMB 89.55 million in 2022, approximately RMB 167.45 million in 2023, and approximately RMB 108.92 million in 2024, with RMB 63.40 million and RMB 48.70 million for the six months ending June 30 in 2024 and 2025, respectively [6]. - Gross profit margins were 16.4% in 2022, 18.9% in 2023, and 18.1% in 2024, with a margin of 15.9% for the six months ending June 30 in 2025 [7][9]. Industry Overview - The private hospital sector in China is predominantly for-profit, holding a market share of 66.5% in 2024. The revenue of private hospitals is projected to grow from RMB 437.9 billion in 2019 to RMB 944.7 billion in 2024, with a compound annual growth rate (CAGR) of 16.6% [10]. - The number of private hospitals is expected to increase from 22,424 in 2019 to 27,652 in 2024, with a CAGR of 4.3% [13]. - The demand for higher quality medical services is anticipated to rise due to increasing disposable income and changing patient preferences, positioning private hospitals as key players in meeting this demand [13].